Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chemo-free cocktail tame mantle cell lymphoma?

NCT ID NCT07719556

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase II trial is testing whether a combination of three targeted drugs—orelabrutinib, obinutuzumab, and a short course of venetoclax—can effectively treat people newly diagnosed with mantle cell lymphoma (MCL). The study will enroll about 39 participants who have not received prior treatment. Researchers aim to see how many patients achieve a complete response and whether the cancer cells become undetectable at a molecular level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of three drugs: orelabrutinib, obinutuzumab, and venetoclax
What this could lead to
If successful, this three-drug combination could offer a more effective, chemotherapy-free option for people newly diagnosed with mantle cell lymphoma, potentially leading to deeper remissions.
What could go wrong
This is an early-phase trial with only 39 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will outperform standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Changzhou Second People's Hospital

    RECRUITING

    Changzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiangsu province Hospital

    RECRUITING

    Nanjing, Jiangsu, 210029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.